Biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) said on Friday that it has earned a USD15m in milestone payment from Pfizer Inc following European Commission (EC) approval of TALZENNA (talazoparib) for the treatment of adult patients with metastatic breast cancer (MBC).
The European Commission EC has approved TALZENNA (talazoparib) for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA) 1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC).
Earlier in 2015, Medivation Inc and BioMarin Pharmaceutical Inc launched an asset purchase agreement, under which Medivation acquired all worldwide rights to talazoparib, a once-daily, oral poly (ADP-ribose) polymerase (PARP) inhibitor. Medivation was later acquired by Pfizer in September 2016.
In conjunction with the agreement, Medivation paid BioMarin USD410m upfront and BioMarin is entitled to receive up to an additional USD160m (in aggregate) upon the achievement of regulatory and sales-based milestones, of which USD50m has been earned to date, as well as mid-single digit royalties for talazoparib.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories